Market News AIOpen the app

CLDX stock news · Celldex Therapeutics, Inc.

Stories about Celldex Therapeutics, Inc. (CLDX) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for CLDX

Follow Celldex Therapeutics, Inc. (CLDX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CLDX
Free on the App Store and Google Play, or on the web.
  1. Nov 20, 2026, 6:05 PM ET · Opinion

    H.C. Wainwright cut its price target for Celldex Therapeutics from $64.00 to $58.00 but still rates it a 'Buy.

    Neutral

    H.C. Wainwright cut its Celldex share-price target from $64 to $58 but kept its Buy rating.

  2. Nov 19, 2026, 6:06 PM ET · Trial

    Celldex said its Phase 2 study of barzolvolimab for atopic dermatitis did not achieve its main goals.

    Bad for CLDX

    Celldex's Phase 2 atopic dermatitis study missed its main measures and its bar for continued work. This is bad news for that use, despite earlier positive results elsewhere.

  3. Sep 22, 2026, 7:21 AM ET · Market

    Celldex Therapeutics, Inc. shares news about its Barzolvolimab trials for chronic hives.

    Neutral

    The filing attaches a press release about two Phase 3 trials but contains no trial results. It does not change Celldex's outlook.